{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:19:25Z","timestamp":1785521965650,"version":"3.56.0"},"reference-count":49,"publisher":"MJH Life Sciences","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>PURPOSE: Metastatic prostate cancer treatment has evolved in\nthe past few decades, finding targeted therapy in the homologous\nrecombination repair (HRR) pathway and mismatch repair (MMR)\ndeficiency.\nMETHODS: This cross-sectional study evaluated men with\nmetastatic prostate cancer treated at a referral center in Mexico\nCity, Mexico. Next-generation sequencing was used. MMR status\nwas evaluated via immunohistochemistry. This study aimed to\ncharacterize the genetic landscape in a cohort of Mexican patients.\nRESULTS: Among 186 patients who underwent somatic testing,\n101 also had germline testing. Age at diagnosis was 68 years\n(range, 41-90), 52.7% had de novo metastatic disease, and 35.5%\nhad metastatic castration-resistant disease. A total of 52 somatic\npathogenic variants (PVs) in HRR genes were identified in 45\npatients (24.2%); ATM, PALB2, CHEK2, and BRCA2 were the most\ncommon. Among 101 individuals with germline genetic testing, 12\n(11.8%) carried germline PVs, most frequently in ATM and CHEK2. A\nhigher proportion of germline PV carriers was observed in patients\nwith HRR-positive tumors (28.6% vs 4.1%; P = .001). MMR deficiency\nwas found in 3 out of 140 patients (2.1%).\nCONCLUSION: Although the overall frequency of PVs is consistent\nwith that reported in other populations, the spectrum of PVs may\nreflect a distinct molecular profile among Mexican patients with\nmetastatic prostate cancer.\nKEYWORDS: Prostatic neoplasms\/genetics, DNA repair\/genetics,\ngermline mutation, genetic testing\/methods, health care disparities.<\/jats:p>","DOI":"10.46883\/2026.25921234","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:09:44Z","timestamp":1785517784000},"source":"Crossref","is-referenced-by-count":0,"title":["Homologous Recombination and Mismatch Repair Assessment in Men With Advanced Prostate Cancer: A Cross-Sectional Study From a Center in Mexico City"],"prefix":"10.46883","volume":"40","author":[{"given":"Jos\u00e9 Luis","family":"Rodr\u00edguez-Olivares","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00xgvev73","id-type":"ROR","asserted-by":"publisher"}],"name":"Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio Mora","family":"Pineda","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00xgvev73","id-type":"ROR","asserted-by":"publisher"}],"name":"Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn L. Beas","family":"Lozano","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00xgvev73","id-type":"ROR","asserted-by":"publisher"}],"name":"Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alec","family":"Seidman-Sorsby","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00xgvev73","id-type":"ROR","asserted-by":"publisher"}],"name":"Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuly A.","family":"Remolina-Bonilla","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00xgvev73","id-type":"ROR","asserted-by":"publisher"}],"name":"Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Gamboa-Dominguez","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00xgvev73","id-type":"ROR","asserted-by":"publisher"}],"name":"Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey N.","family":"Weitzel","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00cj35179","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Kansas Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Barata","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02kb97560","id-type":"ROR","asserted-by":"publisher"}],"name":"University Hospitals Seidman Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanin","family":"Chavarri-Guerra","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00xgvev73","id-type":"ROR","asserted-by":"publisher"}],"name":"Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria T.","family":"Bourlon","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00xgvev73","id-type":"ROR","asserted-by":"publisher"}],"name":"Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"25947","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"ref0","unstructured":"Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: cancer Today. IARC; 2024. Accessed April 8, 2025. https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/900-world-fact-sheet.pdf"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Torres-S\u00e1nchez L, Hern\u00e1ndez-P\u00e9rez JG, Escamilla-Nu\u00f1ez C, et al. Disparities on prostate cancer survival in Mexico: a retrospective cohort study. Salud Publica Mex. 2023;65(3):236-244. doi:10.21149\/14266","DOI":"10.21149\/14266"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Torres-Roman JS, Valcarcel B, Arce-Huamani MA, et al. Prostate cancer in Latin America and the Caribbean: mortality trends from 1997 to 2017 and predictions to 2030. Salud Publica Mex. 2024;66(3):226-235. doi:10.21149\/15463","DOI":"10.21149\/15463"},{"key":"ref3","unstructured":"NCCN. Clinical Practice Guidelines in Oncology. Prostate cancer, version 1.2025. Accessed May 19, 2025. https:\/\/www.nccn.org\/guidelines\/guidelines-detail"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Yu EY, Rumble RB, Agarwal N, et al. Germline and somatic genomic testing for metastatic prostate cancer: ASCO guideline. J Clin Oncol. 2025;43(6):748-758.. doi:10.1200\/JCO-24-02608","DOI":"10.1200\/JCO-24-02608"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Stopsack KH, Vijai J, Conry M, et al. Germline DNA damage repair variants and prognosis of patients with high-risk or metastatic prostate cancer. Clin Cancer Res. 2025;31(1):122-129. doi:10.1158\/1078-0432.CCR-24-2483","DOI":"10.1158\/1078-0432.CCR-24-2483"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Angel M, Freile B, Rodriguez A, et al. Genomic landscape in prostate cancer in a Latin American population. JCO Glob Oncol. 2024;10:e2400072. doi:10.1200\/GO.24.00d072","DOI":"10.1200\/GO.24.00072"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Blazer KR, Chavarri-Guerra Y, Villarreal Garza C, et al. Development and pilot implementation of the Genomic Risk Assessment for Cancer Implementation and Sustainment (GRACIAS) intervention in Mexico. JCO Glob Oncol. 2021;7:992-1002. doi:10.1200\/GO.20.00587","DOI":"10.1200\/GO.20.00587"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Nicolosi P, Ledet E, Yang S, et al. Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines. JAMA Oncol. 2019;5(4):523-528. doi:10.1001\/jamaoncol.2018.6760","DOI":"10.1001\/jamaoncol.2018.6760"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"The Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell. 2015;163(4):1011-1025. doi:10.1016\/j.cell.2015.10.025","DOI":"10.1016\/j.cell.2015.10.025"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Pritchard CC, Mateo J, Walsh MF, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375(5):443-453. doi:10.1056\/nejmoa1603144","DOI":"10.1056\/NEJMoa1603144"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Manneh R, Verson CA, Martin A, et al. Prospective study of homologous recombination repair gene mutation prevalence in patients with advanced prostate cancer from Latin America: challenges and future approaches. JCO Precis Oncol. 2024;8:e2300628. doi:10.1200\/po.23.00628","DOI":"10.1200\/PO.23.00628"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972;22(4):232-240. doi:10.3322\/canjclin.22.4.232","DOI":"10.3322\/canjclin.22.4.232"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382(22):2091-2102. doi:10.1056\/nejmoa1911440","DOI":"10.1056\/NEJMoa1911440"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Fizazi K, Piulats JM, Reaume MN, et al. Rucaparib or physician's choice in metastatic prostate cancer. N Engl J Med. 2023;388(8):719-732. doi:10.1056\/nejmoa2214676","DOI":"10.1056\/NEJMoa2214676"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Bryce AH, McDermott RS, Piulats JM, et al. Rucaparib vs docetaxel (DTX) or second-generation androgen pathway inhibitor (ARPI) therapy for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 final overall survival (OS) and safety. J Clin Oncol. 2025;43(suppl 5):155. doi:10.1200\/JCO.2025.43.5_suppl.155","DOI":"10.1200\/JCO.2025.43.5_suppl.155"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Clarke NW, Armstrong AJ, Thiery-Vuillemin A, et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evid. 2022;1(9):EVIDoa2200043. doi:10.1056\/EVIDoa2200043","DOI":"10.1056\/EVIDoa2200043"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Chi KN, Sandhu S, Smith MR, et al. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. Ann Oncol. 2023;34(9):772-782. doi:10.1016\/j.annonc.2023.06.009","DOI":"10.1016\/j.annonc.2023.06.009"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Agarwal N, Azad AA, Carles J, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet. 2023;402(10398):291-303. doi:10.1016\/S0140-6736(23)01055-3","DOI":"10.1016\/S0140-6736(23)01055-3"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Agarwal N, Azad A, Carles J, et al. Final overall survival (OS) with talazoparib (TALA)\u2009+\u2009enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial. J Clin Oncol. 2025;43(suppl 5):LBA18. doi:10.1200\/JCO.2025.43.5_suppl.LBA18","DOI":"10.1200\/JCO.2025.43.5_suppl.LBA18"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Boscolo Bielo L, Trapani D, Repetto M, et al. Variant allele frequency: a decision-making tool in precision oncology? Trends Cancer. 2023;9(12):1058-1068. doi:10.1016\/j.trecan.2023.08.011","DOI":"10.1016\/j.trecan.2023.08.011"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Antonarakis ES, Piulats JM, Gross-Goupil M, et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol. 2020;38(5):395-405. doi:10.1200\/JCO.19.01638","DOI":"10.1200\/JCO.19.01638"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352-360. doi:10.1056\/nejmoa1704174","DOI":"10.1056\/NEJMoa1704174"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737-746. doi:10.1056\/nejmoa1503747","DOI":"10.1056\/NEJMoa1503747"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Shui IM, Burcu M, Shao C, et al. Real-world prevalence of homologous recombination repair mutations in advanced prostate cancer: an analysis of two clinico-genomic databases. Prostate Cancer Prostatic Dis. 2024;27(4):728-735. doi:10.1038\/s41391-023-00764-1","DOI":"10.1038\/s41391-023-00764-1"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Shore N, Ionescu-Ittu R, Yang L, et al. Real-world genetic testing patterns in metastatic castration-resistant prostate cancer. Future Oncol. 2021;17(22):2907-2921. doi:10.2217\/fon-2021-0153","DOI":"10.2217\/fon-2021-0153"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Barata PC, Assayag J, Li B, Siu G, Niyazov A. Genetic testing in men with metastatic castration-resistant prostate cancer. JAMA Oncol. 2024;10(7):975-977. doi:10.1001\/jamaoncol.2024.0851","DOI":"10.1001\/jamaoncol.2024.0851"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Ch\u00e1varri-Guerra Y, Bourlon MT, Rodr\u00edguez-Olivares JL, et al. Germline DNA repair genes pathogenic variants among Mexican patients with prostate cancer. Clin Genitourin Cancer. 2023;21(5):569-573. doi:10.1016\/j.clgc.2023.05.012","DOI":"10.1016\/j.clgc.2023.05.012"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Shore ND, Vasudevan A, Li J, et al. Real-world clinical practice gaps in timely homologous recombination repair gene mutation (HRRm) testing and poly (ADP-ribose) polymerase inhibitor (PARPi) treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2025;43(suppl 5):85. doi:10.1200\/JCO.2025.43.5_suppl.85","DOI":"10.1200\/JCO.2025.43.5_suppl.85"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Olmos D, Lorente D, Jambrina A, et al. BRCA1\/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes. Ann Oncol. 2025;36(10):1190-1202. doi:10.1016\/j.annonc.2025.05.534","DOI":"10.1016\/j.annonc.2025.05.534"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Mateo J, Seed G, Bertan C, et al. Genomics of lethal prostate cancer at diagnosis and castration resistance. J Clin Invest. 2020;130(4):1743-1751. doi:10.1172\/JCI132031","DOI":"10.1172\/JCI132031"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Warner E, Herberts C, Fu S, et al. BRCA2, ATM, and CDK12 defects differentially shape prostate tumor driver genomics and clinical aggression. Clin Cancer Res. 2021;27(6):1650-1662. doi:10.1158\/1078-0432.CCR-20-3708","DOI":"10.1158\/1078-0432.CCR-20-3708"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Schweizer MT, Sivakumar S, Tukachinsky H, et al. Concordance of DNA repair gene mutations in paired primary prostate cancer samples and metastatic tissue or cell-free DNA. JAMA Oncol. 2021;7(9):1378-1382. doi:10.1001\/jamaoncol.2021.2350","DOI":"10.1001\/jamaoncol.2021.2350"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Nicolosi P, Heald B, Esplin ED. What is a variant of uncertain significance in genetic testing? Eur Urol Focus. 2022;8(3):654-656. doi:10.1016\/j.euf.2022.03.018","DOI":"10.1016\/j.euf.2022.03.018"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Walsh N, Cooper A, Dockery A, O'Byrne JJ. Variant reclassification and clinical implications. J Med Genet. 2024;61(3):207-211. doi:10.1136\/jmg-2023-109488","DOI":"10.1136\/jmg-2023-109488"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Kobayashi Y, Chen E, Facio FM, et al. Clinical variant reclassification in hereditary disease genetic testing. JAMA Netw Open. 2024;7(11):e2444526. doi:10.1001\/jamanetworkopen.2024.44526","DOI":"10.1001\/jamanetworkopen.2024.44526"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Mahal BA, Alshalalfa M, Kensler KH, et al. Racial differences in genomic profiling of prostate cancer. N Engl J Med. 2020;383(11):1083-1085. doi:10.1056\/NEJMc2000069","DOI":"10.1056\/NEJMc2000069"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Arfat Ganiyani M, Prabhakar P, Aman Khosla A, et al. Impact of TP53, RB1, and PTEN mutations on overall survival in metastatic prostate cancer: a multi-center study via the Guardian Research Network. J Clin Oncol. 2025;43(suppl 5):82. doi:10.1200\/JCO.2024.42.4_suppl.82","DOI":"10.1200\/JCO.2024.42.4_suppl.82"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Maxwell KN, Cheng HH, Powers J, et al. Inherited TP53 variants and risk of prostate cancer. Eur Urol. 2022;81(3):243-250. doi:10.1016\/j.eururo.2021.10.036","DOI":"10.1016\/j.eururo.2021.10.036"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Castillo D, Yuan TA, Nehoray B, et al. Clonal hematopoiesis and mosaicism revealed by a multi-tissue analysis of constitutional TP53 status. Cancer Epidemiol Biomarkers Prev. 2022;31(8):1621-1629. doi:10.1158\/1055-9965.EPI-21-1296","DOI":"10.1158\/1055-9965.EPI-21-1296"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Gondek LP. CHIP: is clonal hematopoiesis a surrogate for aging and other disease? Hematology Am Soc Hematol Educ Program. 2021;2021(1):384-389. doi:10.1182\/hematology.2021000270","DOI":"10.1182\/hematology.2021000270"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Jensen K, Konnick EQ, Schweizer MT, et al. Association of clonal hematopoiesis in DNA repair genes with prostate cancer plasma cell-free DNA testing interference. JAMA Oncol. 2021;7(1):107-110. doi:10.1001\/jamaoncol.2020.5161","DOI":"10.1001\/jamaoncol.2020.5161"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Grech CT, Pils D, Aust S, et al. Corrected allele frequency of BRCA1\/2 mutations is an independent prognostic factor for treatment response to PARP-inhibitors in ovarian cancer patients. J Pers Med. 2022;12(9):1467. doi:10.3390\/jpm12091467","DOI":"10.3390\/jpm12091467"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Abida W, Cheng ML, Armenia J, et al. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. JAMA Oncol. 2019;5(4):471. doi:10.1001\/jamaoncol.2018.5801","DOI":"10.1001\/jamaoncol.2018.5801"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Barata P, Agarwal N, Nussenzveig R, et al. Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA. J Immunother Cancer. 2020;8(2):e001065. doi:10.1136\/jitc-2020-001065","DOI":"10.1136\/jitc-2020-001065"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Zang PD, Chawla NS, Barragan-Carrillo R, et al. Tumor mutational burden in metastatic castration-resistant prostate cancer and response to checkpoint inhibition. JAMA Oncol. 2024;10(4):531. doi:10.1001\/jamaoncol.2023.6817","DOI":"10.1001\/jamaoncol.2023.6817"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Shore N, Gazi M, Pieczonka C, et al. Efficacy of National Comprehensive Cancer Network guidelines in identifying pathogenic germline variants among unselected patients with prostate cancer: the PROCLAIM trial. Eur Urol Oncol. 2023;6(5):477-483. doi:10.1016\/j.euo.2023.07.008","DOI":"10.1016\/j.euo.2023.07.008"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Shore N, Armstrong AJ, Barata P, et al. Implementing and optimizing universal germline genetic testing for patients with prostate cancer in clinical practice. Urology. 2025;199:1-10. doi:10.1016\/j.urology.2025.01.070","DOI":"10.1016\/j.urology.2025.01.070"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Ch\u00e1varri-Guerra Y, Rodr\u00edguez-Olivares JL, Ram\u00edrez-Gonz\u00e1lez A, et al. Addressing the need for genetic cancer risk assessment in Mexico: from establishment of a formal program to delivery innovation and expansion. Genet Med Open. 2024;2(suppl 2):101874. doi:10.1016\/j.gimo.2024.101874","DOI":"10.1016\/j.gimo.2024.101874"}],"container-title":["ONCOLOGY"],"original-title":[],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:09:52Z","timestamp":1785517792000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cancernetwork.com\/view\/homologous-recombination-mismatch-repair-assessment-men-advanced-prostate-cancer-cross-sectional-study-from-mexico-city"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":49,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,7,22]]}},"URL":"https:\/\/doi.org\/10.46883\/2026.25921234","relation":{},"ISSN":["0890-9091","2767-7389"],"issn-type":[{"value":"0890-9091","type":"print"},{"value":"2767-7389","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]}}}